Document registry — page 30
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in adolescent obesity randomising 201 participants over 68 weeks. Primary result: Mean change…
Moderate13 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low13 Mar 2024 -
Single-arm open-label, phase 3 study of Liraglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low12 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2024 -
Phase 1 ascending dose, phase 1 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Mar 2024 -
Consultation on the draft of this intervention review, which registers the question: In adults with heart failure with preserved ejection fraction and obesity, what is…
11 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low11 Mar 2024 -
Single-arm open-label, phase 3 study of Semaglutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low11 Mar 2024 -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide). Hexarelin is a potent ghrelin receptor agonist producing marked growth-hormone release. Unlike ipamorelin it also stimulates…
Very low10 Mar 2024 -
Single-arm open-label, phase 3 study of Semaglutide, oral in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low10 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 1/2 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Mar 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low08 Mar 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide in cardiovascular and obesity randomising 17,604 participants over mean 39.8 months. Primary…
High07 Mar 2024 -
Observational, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes no…
Very low07 Mar 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Semaglutide in obesity randomising 338 participants over 68 weeks. Primary result: Mean change −15.8 % with…
High06 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low06 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Kisspeptin-10 in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported…
Very low06 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Mar 2024 -
Consultation on the draft monograph for Teduglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low05 Mar 2024 -
Observational, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low04 Mar 2024 -
Randomised crossover, phase 2 study of SS-31 (elamipretide) in mitochondrial disease randomising 30 participants over 4 weeks per period. Primary result: An increase in…
Moderate03 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low02 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low02 Mar 2024 -
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine production in epithelial and immune cells. Reported uptake through the…
Very low01 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low01 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low29 Feb 2024 -
Observational, phase 2 study of Pramlintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low29 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low26 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low25 Feb 2024 -
Randomised withdrawal, phase 3 study of Semaglutide in obesity randomising 803 participants over 48 weeks after a 20-week run-in. Primary result: Continued treatment…
High24 Feb 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,842 participants over 36 weeks. Primary result: Dose-dependent…
High23 Feb 2024
page 30 of 41